We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current AKBA market cap is 303.73M. The company's latest EPS is USD -0.2477 and P/E is -5.81.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 40.13M | 56.25M | 42.05M | 56.2M | 32.61M |
| Operating Income | -24.94M | -9.66M | -13.04M | 1.37M | -14.94M |
| Net Income | -26.22M | -11.83M | -14.49M | 614k | -17.99M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 335M | 295.31M | 213.58M | 292.6M | 194.62M |
| Operating Income | -286.29M | -376.44M | -265.32M | -79.12M | -46.26M |
| Net Income | -279.66M | -383.46M | -282.84M | -92.56M | -51.93M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 276.86M | 253.71M | 235M | 241.7M | 225.48M |
| Total Liabilities | 291.21M | 280.52M | 274.42M | 272.29M | 252.74M |
| Total Equity | -14.35M | -26.81M | -39.42M | -30.58M | -27.26M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 771.2M | 644.14M | 525.55M | 351.83M | 241.7M |
| Total Liabilities | 376.44M | 396.52M | 449.09M | 342.49M | 272.29M |
| Total Equity | 394.76M | 247.62M | 76.46M | 9.34M | -30.58M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -17.54M | -13.91M | -21.08M | -23.38M | -19.43M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | -15.97M | -23.97M | -23.92M | -25.21M | 18.48M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -257.44M | -110.39M | -252.97M | -73.15M | -23.38M |
| Investing | 211.18M | -40M | 39.94M | -114k | N/A |
| Financing | 88.97M | 231.72M | 133.73M | 14.6M | -25.21M |
| Market Cap | 303.73M |
| Price to Earnings Ratio | -5.81 |
| Price to Sales Ratio | 1.55 |
| Price to Cash Ratio | 7.03 |
| Price to Book Ratio | -9.87 |
| Dividend Yield | - |
| Shares Outstanding | 209.6M |
| Average Volume (1 week) | 2.28M |
| Average Volume (1 Month) | 2.82M |
| 52 Week Change | -0.75% |
| 52 Week High | 2.48 |
| 52 Week Low | 0.7801 |
| Spread (Intraday) | 0.02 (1.38%) |
| Company Name | Akebia Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.akebia.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
